Trial Profile
Ice-CAP: A Phase I Trial of Ipatasertib in Combination With Atezolizumab in Patients With Advanced Solid Tumours With PI3K Pathway Hyperactivation
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Ipatasertib (Primary)
- Indications Glioblastoma; Prostate cancer; Solid tumours
- Focus Adverse reactions; Proof of concept
- Acronyms IceCAP
- 19 Apr 2023 Results(n=23) hypothesizing that Akt inhibition in PTEN loss glioblastomas may deplete the TME of suppressive immune cells, and render malignant brain tumors more responsive to ICIs presented at the 114th Annual Meeting of the American Association for Cancer Research
- 31 Mar 2022 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.
- 31 Mar 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Nov 2023.